Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Lovenox Battle Heats Up With Amphastar’s ANDA Approval

Executive Summary

Momenta Pharmaceuticals and Sandoz have enjoyed approximately 14 months of de facto generic exclusivity on Sanofi’s anticoagulant Lovenox (enoxaparin), but faced with the imminent threat of competition they are trying to maintain their hold on the market through patent litigation.

You may also be interested in...



Momenta And Sandoz Pay $120m To Settle Enoxaparin Suit

Momenta and Sandoz must hand over $120m between them to a range of enoxaparin purchasers following final approval of a settlement agreement resolving claims the pair unfairly conspired to block further generic competition in the US to Sanofi’s Lovenox blood-thinner.

Amphastar Will Receive $59.9m In Momenta/Sandoz Settlement

The small generics company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.

Amphastar Poised To Receive $59.9m In Momenta/Sandoz Settlement

The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel